🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Dragon PLC Trial (DRAGON-PLC)

RecruitingNAAges 18 Years - anyAllMaastricht University
NCT06914648 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhancing liver hypertrophy. Participants will: * Undergo either standard PVE or combined PVE and HVE. * Have regular imaging to assess liver resectability. * Be monitored for survival outcomes up to 5 years after intervention.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * PLC diagnosis, specifically iCCC, pCCC, and HCC; * Requiring PVE due to an FLR volume is \<30% in normally functioning livers, \<40% in livers with potentially impaired function e.g. resulting from prior systemic therapy induction or bile duct colonization / transpapillary biliary drainage, or \<50% in livers with severely impaired function resulting from liver cirrhosis (max. Child Pugh A5) OR function on hepatobiliary scintigraphy (HEBIS) is \< 2.7 %/min/m2; * Age ≥ 18 years; * Able to understand the trial and provide informed consent. Exclusion Criteria: * Liver cirrhosis with a Child-Pugh score of B or C; * Presence of portal hypertension; * Presence of cholangitis; * Pregnant women; * Premenopausal females not able/willing to commit to contraception (specifically long-acting reversible contraception or hormonal contraception); * Patients unresectable due to prohibitive comorbidities (decision made by local multidisciplinary team); * Patients with hepatic malignancies other than iCCC, pCCC or HCC; * PVE/HVE anatomically not feasible; * Any patient with non-resectable or non-ablatable extrahepatic metastatic disease. * Unable to understand the study information, study instructions and give informed consent
💊

What it tests

  • Portal Vein Embolization
  • Hepatic Vein Embolization
📍

Where

55 sites
Yale School of Medicine Hospital
New Haven, United States
Rush University Medical Center
Chicago, United States
Mayo Clinic
Rochester, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Cleveland Clinic
Cleveland, United States
Monash Medical Center
Melbourne, Australia
Medical University of Vienna
Vienna, Austria
Social Center South
Vienna, Austria

…and 47 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy